What Labcorp's latest 10-Q says: 7 signals
Labcorp filed its latest 10-Q with the SEC on Aug 5, 2026. It discusses automation investment, capex increase and debt refinancing.
Public (LH)Hospitals and Health Care10,000+ employeeslabcorp.comLinkedIn
- Filed
- Aug 5, 2026
- Filings
- 2
- Signals
- 14
10-Q · latest 10
What Labcorp's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 7 signals
Labcorp increases H1 capital expenditures 24% to $252.6M and commits to a $155M acquisition.
$252.6M
Capital expenditures for the six months ended June 30, 2026
23.8%
Year-over-year increase in capital expenditures for the six month period
Labcorp boosts H1 CapEx 24% to $252.6M for advanced technology and integration
The company has significantly increased capital expenditures year-over-year, explicitly earmarking funds to 'implement advanced technology' and support 'acquisition integration activities'.
$252.6M
Capital expenditures for the six months ended June 30, 2026
23.9%
Year-over-year increase in capital expenditures for the first six months
advanced technologyMoody'sS&P Global RatingsU.S. Bank Trust Company, National Association
Labcorp secures new $750M term loan and amends AR facility to manage debt.
The company is actively managing its capital structure by taking on a new term loan to redeem senior notes and extending its AR facility.
$750M
New 2026 Term Loan entered into on March 20, 2026
SOFRU.S. Bank Trust Company, National Association
Labcorp cites 'operating efficiencies' as key driver for margin growth across business segments
Management repeatedly credited 'operating efficiencies' for margin improvements in both its Diagnostics and Biopharma Laboratory Services segments, including a 100 basis point increase in the BLS segment.
1%
BLS segment operating margin increase (100 basis points)
Moody'sS&P Global RatingsU.S. Bank Trust Company, National Association
EVP of Operations and a Director adopt Rule 10b5-1 trading plans in May 2026.
Jonathan C. Meltzer (EVP, Chief Operations Officer) and Kerrii B.
Labcorp's international revenue grows to 13.9% of total revenue
The share of revenue from non-USD currencies has increased year-over-year, with key exposures in Canada, Switzerland, the Eurozone, and the UK.
13.9%
Percentage of revenues denominated in currencies other than the USD
- SEC EDGAR
10-Q
Filed · 7 signals
Labcorp secured a new $750M term loan in March 2026 for debt repayment and corporate use
The company entered a new term loan agreement on March 20, 2026, providing significant capital.
$750M
New 2026 Term Loan proceeds
Wells Fargo Bank, N.A.
Labcorp plans to spend up to $165M to acquire assets from Parkview Health System in 2026
This deal, expected to close in 2026, will require significant post-merger integration efforts, including systems consolidation, process alignment, and potential IT infrastructure upgrades.
$165M
Expected payment for pending acquisition of assets from Parkview Health System
Labcorp prioritizes acquisition integration as part of its $121M Q1 capital expenditure
A key focus of Labcorp's capital expenditure is integrating acquired businesses, suggesting a strategic initiative to create a unified operational and IT platform.
$121M
Capital expenditures for Q1 2026, which includes funding for acquisition integration
Wells Fargo Bank, N.A.
Labcorp invests $121M in Q1 CapEx, focusing on facility expansion and updates
Labcorp is actively spending on expanding and updating its physical footprint, indicating a focus on market growth and operational modernization.
$121M
Capital expenditures for the three months ended March 31, 2026
Showing 10 of 14 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Labcorp earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Investing heavily in AI and digital tools for lab operations and diagnosticsThe company is actively investing in and deploying AI, automation, and digital pathology to enhance diagnostic speed, improve turnaround times, and increase operational efficiency. This includes a generative AI tool with AWS and digital pathology with Roche, signaling significant tech budget for advanced solutions. | |
| Spent $268M on acquisitions in Q3 with a robust pipeline remainingLabcorp is aggressively expanding its network and market presence through acquisitions, having spent $268M in the quarter and announcing multiple new deals. This creates significant opportunities for integration services, IT consolidation, and other vendor solutions to support newly acquired assets. | |
| Raised full-year EPS and Free Cash Flow guidance, signaling strong financial healthThe company raised its midpoint guidance for both adjusted EPS and free cash flow, indicating better-than-expected performance and strong cash generation. This financial strength and available cash flow supports continued investment in strategic initiatives and technology. | |
| Restructuring Early Development business due to softness and delayed studiesThe company is divesting or restructuring sites representing approximately $50 million in annual revenue within its Early Development business due to lower-than-expected revenue and delayed study starts. This signals an urgent need for operational efficiency, asset management, and potentially M&A integration services to streamline the business. | |
| Launching multiple new tests in high-growth specialty and consumer areasThe company is expanding its portfolio with new tests in oncology, neurology, and consumer health, including an FDA-cleared Alzheimer's blood test and at-home colorectal cancer screening. These launches indicate a focus on innovation and market expansion, requiring investment in commercialization, marketing, and operational support. | |
| Aggressively acquiring labs and outreach businesses with robust pipelineThe company is executing a strong M&A strategy, closing multiple acquisitions and investing $268 million in Q3 alone, with a 'very robust pipeline' of future opportunities. This creates needs for M&A advisory, due diligence, and post-merger integration services and technologies. |
Signal API · MCP
Track Labcorp with the Signal API
One POST /v1/companies/enrich call with labcorp.com returns Labcorp 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"labcorp.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Labcorp 10-Q
When did Labcorp file its latest 10-Q?
What did Labcorp disclose in its latest 10-Q?
What did Labcorp say on its recent earnings calls?
Where can I read Labcorp's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .